Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime

Clin Infect Dis. 2020 Dec 17;71(10):2713-2716. doi: 10.1093/cid/ciaa355.

Abstract

We report 2 independent patients from whom carbapenem and ceftazidime-avibactam-resistant Enterobacter cloacae complex strains were identified. The ceftazidime-avibactam resistance was attributed to a 2-amino acid deletion in the R2 loop of AmpC β-lactamase, which concurrently caused resistance to cefepime and reduced susceptibility to cefiderocol, a novel siderophore cephalosporin.

Keywords: R2 loop; cefepime; deletion; β-lactamase.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Azabicyclo Compounds
  • Bacterial Proteins / genetics
  • Cefepime
  • Cefiderocol
  • Ceftazidime / pharmacology
  • Cephalosporins* / pharmacology
  • Drug Combinations
  • Enterobacter cloacae* / genetics
  • Humans
  • Microbial Sensitivity Tests
  • beta-Lactamases / genetics

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Bacterial Proteins
  • Cephalosporins
  • Drug Combinations
  • avibactam, ceftazidime drug combination
  • Cefepime
  • Ceftazidime
  • beta-Lactamases